Assessment of a radiomic signature developed in a general NSCLC cohort for predicting overall survival of ALK-positive patients with different treatment types

This preliminary study suggests that the applicability of a general signature to ALK patients is limited. The general radiomic signature seems to be only applicable to ALK patients who had received nontargeted therapy, which indicates that developing special radiomics signatures for patients treated with tyrosine kinase inhibitors might be necessary.